KPTI Karyopharm Therapeutics Inc.

9.07
+0.27  (+3%)
Previous Close 8.8
Open 8.75
Price To Book 6.82
Market Cap 561,619,089
Shares 61,920,517
Volume 1,889,203
Short Ratio
Av. Daily Volume 2,526,054

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due in 2020.
Selinexor - SEAL
Dedifferentiated liposarcoma
FDA Approval announced July 3, 2019. Continued approval may be contingent upon data from its Phase 3 Boston trial (data due late-2019/early 2020).
Selinexor
Quadruple Refractory Multiple Myeloma
Phase 3 data due end of 2019 or into 2020.
Selinexor - BOSTON
Multiple myeloma
NDA filing due 4Q 2019 or 1Q 2020.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 enrolment to be completed 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data reported at ASCO-GU 2019.
Eltanexor
Solid tumors
Phase 1/2 updated tolerability data due 2019.
KPT-9274
Non-Hodgkin Lymphoma

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
  2. CLASS ACTION NOTICE: Brodsky & Smith, LLC Is Investigating Securities Violations
  3. SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
  4. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of EROS, KPTI and GTT
  5. SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  6. CLASS ACTION UPDATE for DBD, OMCL and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  7. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
  8. CLASS ACTION UPDATE for OMCL, KPTI and CAH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  9. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Class Action - Bronstein, Gewirtz & Grossman, LLC
  10. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of RLGY, RBGLY and KPTI
  11. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, CARB and CAH
  12. CLASS ACTION UPDATE: Brodsky & Smith, LLC Announces Investigation of Securities Violations
  13. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EROS, OMCL and KPTI
  14. IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  15. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of NFLX, KPTI and IFF
  16. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
  17. The Gross Law Firm Announces Class Actions on Behalf of Shareholders of EQT, KPTI and EVH